Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4461-4470 Newer>

The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool December 31, 2007 Brian Lawler	Lower Expectations for Theravance The FDA decides to debate Theravance's lead drug, Telavancin, leading to a drop in share price.
The Motley Fool December 31, 2007 Brian Orelli	Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed.
The Motley Fool December 31, 2007 Brian Lawler	Does Leadership Count at the FDA? Let's take a look at how drug approval rates have fared under different FDA commissioners.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool December 28, 2007 Brian Lawler	Investors Wary on Noven Approval Noven Pharmaceuticals announces that the FDA has issued a tentative approval for one of its drugs, yet shares are trading lower since the news. Is the "tentative" status making investors jittery?
The Motley Fool December 28, 2007 Brian Lawler	Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
The Motley Fool December 28, 2007 Brian Orelli	The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007.
The Motley Fool December 28, 2007 Brian Orelli	Investing in a Purchased Company Billionaire investor Steven Cohen, through his hedge fund SAC Capital Advisors, ups his stake in biotech company Pharmion. Let's take a look at why.
<Older 4461-4470 Newer> Return to current articles.